Psoriasis

Immunology
136
Pipeline Programs
30
Companies
22
Clinical Trials
4 recruiting
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
39
1
32
2
40
22
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3788%
Small Molecule
512%
+ 135 programs with unclassified modality

On Market (6)

Approved therapies currently available

UP
CIMZIAApproved
certolizumab pegol
UCB Pharma
Tumor Necrosis Factor Blocker [EPC]injection2008
U
ENBRELApproved
etanercept
Unknown Company
Tumor Necrosis Factor Blocker [EPC]subcutaneous1998
AbbVie
HUMIRAApproved
adalimumab
AbbVie
2002
Amgen
OTEZLAApproved
apremilast
Amgen
oral2025
Amgen
OTEZLA XRApproved
apremilast
Amgen
oral2025
Bristol Myers Squibb
SOTYKTUApproved
deucravacitinib
Bristol Myers Squibb
Tyrosine Kinase 2 Inhibitor [EPC]oral2022

Competitive Landscape

45 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
20 programs
1
2
7
4
ApremilastPhase 41 trial
Enbrel®Phase 41 trial
etanerceptPhase 41 trial
etanerceptPhase 41 trial
1=EtanerceptPhase 31 trial
+15 more programs
Active Trials
NCT03757013Completed453Est. Sep 2021
NCT03097003Completed124Est. Dec 2018
NCT00930592Completed42Est. Dec 2012
+16 more trials
AbbVie
18 programs
8
1
RisankizumabPhase 3Monoclonal Antibody1 trial
RisankizumabPhase 3Monoclonal Antibody1 trial
RisankizumabPhase 3Monoclonal Antibody1 trial
risankizumabPhase 3Monoclonal Antibody
risankizumabPhase 3Monoclonal Antibody1 trial
+13 more programs
Active Trials
NCT01320293Completed18Est. Mar 2015
NCT04799990Withdrawn0Est. Mar 2022
NCT03048721Completed15Est. Sep 2018
+14 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
16 programs
4
5
1
3
BrodalumabPhase 4Monoclonal Antibody1 trial
IDP-118 LotionPhase 41 trial
IDP-122 LotionPhase 41 trial
210 mg brodalumabPhase 3Monoclonal Antibody1 trial
70 mg SCPhase 21 trial
+11 more programs
Active Trials
NCT03254667Enrolling By InvitationEst. Nov 2031
NCT05132231Active Not RecruitingEst. Mar 2026
NCT04149587CompletedEst. Mar 2022
+13 more trials
GSK
GSKLONDON, United Kingdom
11 programs
2
3
3
3
Acitretin 17.5 mg/dayPhase 41 trial
Clobetasol propionate foamPhase 41 trial
vehicle foamPhase 41 trial
Calcipotriene FoamPhase 31 trial
U0267Phase 31 trial
+6 more programs
Active Trials
NCT01702493Completed16Est. Dec 2012
NCT01984775Completed52Est. Jul 2014
NCT00716144Completed176Est. May 2007
+8 more trials
UP
7 programs
1
1
3
1
Certolizumab PegolPhase 31 trial
Certolizumab PegolPhase 31 trial
Certolizumab PegolPhase 31 trial
Certolizumab PegolPhase 21 trial
UCB5857 Part 1Phase 11 trial
+2 more programs
Active Trials
NCT02303509Completed57Est. Feb 2014
NCT00329303Completed71Est. May 2007
NCT02346240Completed559Est. Dec 2018
+2 more trials
Bristol Myers Squibb
4 programs
2
DeucravacitinibPhase 4Small Molecule1 trial
DeucravacitinibPhase 4Small Molecule1 trial
PsoBest - The German Psoriasis RegistryN/A
Spanish Registry of Systemic Treatments in PsoriasisN/A
Active Trials
NCT05478499Completed154Est. Oct 2024
NCT05701995Completed180Est. May 2025
Genentech
4 programs
2
2
efalizumabPhase 4Monoclonal Antibody1 trial
efalizumabPhase 4Monoclonal Antibody1 trial
RaptivaPhase 31 trial
RaptivaPhase 31 trial
Active Trials
NCT00109252Completed0Est. Apr 2003
NCT00096603Completed450Est. Jul 2004
NCT00669214Completed89Est. Jan 2009
+1 more trials
Verona Pharma
2 programs
2
SecukinumabPhase 4Monoclonal Antibody1 trial
Weight LossPhase 41 trial
Active Trials
NCT04469829Unknown70Est. Dec 2022
NCT01439425Unknown42Est. Nov 2012
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
19 programs
5
7
6
BI 695501Phase 31 trial
Humira®Phase 31 trial
RisankizumabPhase 3Monoclonal Antibody1 trial
risankizumabPhase 3Monoclonal Antibody1 trial
risankizumabPhase 3Monoclonal Antibody1 trial
+14 more programs
Active Trials
NCT00848055Completed40
NCT01577550Completed39Est. May 2014
NCT05728489Completed64Est. Feb 2025
+15 more trials
Abbott
AbbottABBOTT PARK, IL
6 programs
3
HumiraPhase 31 trial
adalimumabPhase 3Monoclonal Antibody1 trial
adalimumabPhase 3Monoclonal Antibody1 trial
4 mm punch biopsiesN/A1 trial
Greek Study of the Quality of Life in Patients With Psoriasis Treated With AdalimumabN/AMonoclonal Antibody1 trial
+1 more programs
Active Trials
NCT01604902Unknown10Est. Jan 2016
NCT01077128Completed500Est. Sep 2012
NCT01316224Completed52Est. Apr 2014
+3 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
6 programs
2
1
1
80 mg ixekizumab Dosing RegimenPhase 31 trial
teplizumabPhase 1/2Monoclonal Antibody1 trial
LY3316531 - IVPhase 11 trial
LY3361237Phase 11 trial
PsoBest - The German Psoriasis RegistryN/A
+1 more programs
Active Trials
NCT03418493Completed63Est. Jul 2019
NCT04975295Completed21Est. Nov 2022
NCT00954915Terminated1Est. Jul 2010
+1 more trials
M&
Merck & Co.RAHWAY, NJ
5 programs
2
1
MSB11022Phase 3
MK-0873 2% CreamPhase 11 trial
UstekinumabPhase 1Monoclonal Antibody1 trial
PsoBest - The German Psoriasis RegistryN/A
Spanish Registry of Systemic Treatments in PsoriasisN/A
Active Trials
NCT01235728Completed24Est. Apr 2011
NCT01276847Completed40Est. Dec 2011
Biogen
5 programs
3
1
AlefaceptPhase 3
AlefaceptPhase 21 trial
Mechanism of action of alefaceptPhase 21 trial
Transitioning patients from cyclosporine to alefaceptPhase 21 trial
PsoBest - The German Psoriasis RegistryN/A
Active Trials
NCT00301002Completed15Est. Oct 2006
NCT00150982Completed9Est. Feb 2005
NCT00143806Completed13Est. May 2007
Astellas
AstellasChina - Shenyang
2 programs
1
AlefaceptPhase 31 trial
Alefacept exposureN/A1 trial
Active Trials
NCT00454701Terminated1,897Est. Feb 2012
NCT00692172Completed175Est. Nov 2004
Alvotech
2 programs
1
1
StelaraPhase 31 trial
Stelara PFSPhase 11 trial
Active Trials
NCT04744363Completed294Est. Mar 2022
NCT04930042Completed581Est. Oct 2022
Celltrion
CelltrionKorea - Incheon
1 program
1
CT-P43Phase 31 trial
Active Trials
NCT04673786Completed509Est. May 2022
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
1
MSB11022Phase 31 trial
Active Trials
NCT02660580Completed443Est. Dec 2017
E
2 programs
2
Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeksPhase 2/3
adalimumabPhase 2/3Monoclonal Antibody
Pfizer
10 programs
2
2
AN2728Phase 25 trials
CP-690,550 Ointment 1Phase 21 trial
ILV-094Phase 11 trial
PF-06763809Phase 11 trial
Bodystudio ATBMN/A1 trial
+5 more programs
Active Trials
NCT02808559Completed30Est. May 2015
NCT00900952Completed240Est. Jun 2009
NCT00894777Completed469Est. Nov 2009
+10 more trials
Teva
1 program
1
CEP-701 20mgPhase 21 trial
Active Trials
NCT00236119Completed46Est. Oct 2007
Opko Health
Opko HealthMIAMI, FL
1 program
1
CTA018 creamPhase 21 trial
Active Trials
NCT00384098CompletedEst. May 2007
Galectin Therapeutics
1 program
1
GR-MD-02Phase 21 trial
Active Trials
NCT02407041CompletedEst. Mar 2018
Soligenix
SoligenixPRINCETON, NJ
1 program
1
HypericinPhase 21 trial
Active Trials
NCT05442190Completed15Est. Nov 2025
AS
1 program
1
MasitinibPhase 2Small Molecule1 trial
Active Trials
NCT01045577CompletedEst. Feb 2008
Abcentra
AbcentraCA - Los Angeles
1 program
1
OrticumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04776629CompletedEst. Nov 2022
Ventyx Biosciences
Ventyx BiosciencesSAN DIEGO, CA
1 program
1
VTX958 Dose APhase 21 trial
Active Trials
NCT05655299TerminatedEst. Dec 2023
VP
1
VX-765Phase 21 trial
Active Trials
NCT00205465Completed64Est. Sep 2005
BP
Basilea PharmaceuticaSwitzerland - Allschwil
1 program
1
alitretinoinPhase 2
Novartis
NovartisBASEL, Switzerland
6 programs
2
BCT194Phase 11 trial
BCT194Phase 11 trial
Patients receiving PsoPlus careN/A
PsoBest - The German Psoriasis RegistryN/A
Routine practice groupN/A1 trial
+1 more programs
Active Trials
NCT05758402Completed368Est. Jun 2023
NCT02786186Completed2,376Est. Jan 2026
NCT00417820Completed35Est. Nov 2007
+1 more trials
Bayer
3 programs
3
BAY1003803Phase 11 trial
BAY1003803 0.01% lipophilic creamPhase 11 trial
MapracoratPhase 11 trial
Active Trials
NCT02940002Completed23Est. Mar 2017
NCT02936492Terminated32Est. Oct 2017
NCT03399526Completed24Est. May 2013

+15 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AbbVierisankizumab
Bristol Myers SquibbDeucravacitinib
Bristol Myers SquibbDeucravacitinib
AbbVierisankizumab
AbbVierisankizumab
Bausch HealthIDP-118 Lotion
Verona PharmaSecukinumab
Bausch HealthBrodalumab
Bausch HealthIDP-122 Lotion
AmgenApremilast
Amgenetanercept
GSKvehicle foam
Verona PharmaWeight Loss
GSKAcitretin 17.5 mg/day
Genentechefalizumab

Showing 15 of 21 trials with date data

Clinical Trials (22)

Total enrollment: 3,024 patients across 22 trials

Enbrel® in Psoriatic Arthritis

Phase 4Completed
NCT06333860AbbVierisankizumab

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Start: May 2024Est. completion: Mar 2026393 patients
Phase 4Active Not Recruiting

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

Start: Jan 2023Est. completion: May 2025180 patients
Phase 4Completed

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Start: Oct 2022Est. completion: Oct 2024154 patients
Phase 4Completed
NCT04908475AbbVierisankizumab

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Start: Jun 2021Est. completion: Apr 2023352 patients
Phase 4Completed
NCT04630652AbbVierisankizumab

Risankizumab Long-term Remission Study

Start: Apr 2021Est. completion: Jul 202720 patients
Phase 4Active Not Recruiting

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

Start: Mar 2021Est. completion: Mar 2027
Phase 4Recruiting

Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome

Start: Aug 2020Est. completion: Dec 202270 patients
Phase 4Unknown

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Start: Jan 2020Est. completion: Jun 2029
Phase 4Active Not Recruiting

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Start: Oct 2019Est. completion: Jun 2026
Phase 4Recruiting

A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life

Start: Mar 2019Est. completion: Nov 2021277 patients
Phase 4Completed

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

Start: Mar 2014Est. completion: Nov 201750 patients
Phase 4Completed
NCT01745133GSKvehicle foam

Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

Start: Jan 2013Est. completion: Aug 201463 patients
Phase 4Completed

Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis

Start: Nov 2011Est. completion: Nov 201242 patients
Phase 4Unknown
NCT01228409GSKAcitretin 17.5 mg/day

Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

Start: Oct 201020 patients
Phase 4Unknown

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp

Start: Feb 2008Est. completion: Jan 200989 patients
Phase 4Completed
NCT00842153GSKClobetasol propionate foam

Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam

Start: Nov 2007Est. completion: Jan 200858 patients
Phase 4Completed

A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent

Start: May 200673 patients
Phase 4Completed

Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis

Start: Mar 2006Est. completion: Feb 2010246 patients
Phase 4Completed
NCT06880744AbbVierisankizumab

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

Start: Jun 2025Est. completion: Sep 2028530 patients
Phase 3Recruiting
NCT05995353AbbVierisankizumab

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Start: Dec 2023Est. completion: Apr 2029118 patients
Phase 3Recruiting
NCT06063967AbbVierisankizumab

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Start: Nov 2023Est. completion: Mar 2027289 patients
Phase 3Active Not Recruiting

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

40 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 3,024 patients
30 companies competing in this space